Umida F. Mavlyanova, PhD, in a presentation at the American Society for Cataract and Refractive Surgery’s annual meeting in San Diego, detailed how patients diagnosed with end-stage chronic renal failure displayed deceased blood flow in the orbital artery, the central artery of the retina and the posterior short ciliary arteries.
Leo Semes, OD, shares highlights from his presentation on early detection of AMD, which he presented during the 17th annual Controversies in Modern Eye Care.
David Liao, MD, shares highlights from his discussion on evolving treatment strategies for neovascular AMD and DME, during the 17th annual Controversies in Modern Eye Care meeting.
In a sham device-controlled, randomized, double-blind clinical trial in China, researchers utilized a device that emits 650 nm red light directly to the retina.
Deborah Ferrington, PhD, shares a brief overview of her presentation on identifying the mechanism responsible for the death of the retinal pigment epithelium.
Euin Cheong, OD, weighs in on the Syfvore approval for geographic atrophy and how optometrists should participate in geographic atrophy care.
Imaging can elucidate visual prognosis and disease progression risk.
In this first study to provide an in-depth analysis of the retinal proteins, researchers conducted histopathologic and biochemical studies of postmortem retina and brain tissues from 86 human donors.
These disorders account for most of the vision loss in working-age and elderly Americans.
Mohammad Rafieetary, OD, shares key highlights from his VEE 2023 presentation looking at what's hot in retina.
Paul Chous, MA, OD, FAAO, shares key highlights from his 2023 SECO presentation looking at sleep disorders and how they play a role in eye disease.
Andy Lee, MD, gives highlights from his SECO special session, "Neuro nuggets."
Mohammed Rafieetary, OD, shares key takeaways from his SECO 2023 presentation, "Advancing the understanding of geographic atrophy."
Paul Chous, MA, OD, FAAO, gives key takeaways from his 2023 SECO presentation on diabetes: then and now.
The Biologics License Application for aflibercept 8 mg was supported by positive data from the PULSAR study, investigating wet AMD, and the PHOTON study, investigating DME.
Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.
Aflibercept, a VEGF inhibitor previously indicated for a variety of retinal diseases, is the first pharmacological treatment for retinopathy of prematurity in preterm infants.
The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.
These results emphasize the importance of evaluating the midperipheral and peripheral retina in diabetes in addition to the posterior pole and performing ultra-widefield fluorescein angiography for not only accurate diabetic retinopathy staging, but also for likelihood of significant progression based on disease severity and predominantly peripheral lesions.
Leo Semes, OD, FAAO, shares key highlights from his EyeCon 2022 presentation, "Advances in therapies for retinal disease."
Look out for at-risk patients and prepare to establish treatment protocols.
Denise A. Valenti, OD, FAAO, gives key takeaways from her AAOpt 2022 discussion on the impact of marijuana use and driving.
Multiple sclerosis is a neurodegenerative disease with ophthalmic manifestations. Although some cases come to attention following an attack of optic neuritis, embedded optic atrophy can be observed in other, longer-standing cases.
Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.
Case history can give clues to a patient’s risk of developing diabetic eye disease.
